TRANSFUSION TRIAL TO PREVENT PLATELET ALLOLIMMUNIZATION

预防血小板同种免疫的输血试验

• 批准号: 3553361
• 负责人: CHARLES ALAN SCHIFFER
• 金额: $ 45.46万
• 依托单位: UNIVERSITY OF MARYLAND BALTIMORE
• 依托单位国家: 美国
• 财政年份: 1989
• 资助国家: 美国
• 起止时间: 1989-08-01 至 1994-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3553361
• 关键词: MHC class II antigen; acute leukemia; blood donor; clinical trials; histocompatibility; human subject; human tissue; immunohematology; immunosuppression; leukocyte antigen typing; leukocyte depletion therapy; neoplasm /cancer therapy; nonhuman therapy evaluation; platelet transfusion; platelets; radiobiology; ultraviolet radiation

Alloimmunization against histocompatibility antigens occurs in 30-50% of patients with acute non-lymphocytic leukemia and can comprise the delivery of potentially curative post remission therapy. There are a number of potential means of decreasing this incidence, the relative merits of which are discussed in this grant proposal. The University of Maryland Cancer Center (UMCC) is interested in and prepared to participate in randomized clinical trials to compare these various modification of transfusion practice to the standard approach of pooled platelet concentrates from random donors. The UMCC is an excellent environment in which to conduct such studies for the following reasons: (1) there is a well-documented availability of 30-40 new patients with acute non-lymphocytic leukemia suitable for study/annum; (2) the same investigators are responsible for the leukemia and transfusion services guaranteeing a high degree of compliance and randomization; (3) the UMCC has conducted and published multiple studies in the area of transfusion supportive care and platelet immunology; these have included a number of randomized studies, one of which was a randomized trial using leucocyte depleted platelets to modify the rate of alloimmunization; (4) the UMCC has extensive experience in cooperative cancer treatment groups and has facilities for and years of experience with collection and transfer of research data; in addition the UMCC currently enters all platelet transfusion results into a computerized data base used for clinical and research purposes and potentially adaptable for use in this RFA; (5) both investigators on this proposal have chaired and analyzed national group clinical treatment trials and the P.I. currently chairs the Leukemia Committee of the Cancer and Leukemia Group B. A subcontract with the Baltimore Rh Typing laboratory to serve as a reference laboratory to perform lymphocytotoxic antibody screens is submitted as a supplement to the UMCC proposal.

针对组织相容性抗原的同种异体免疫发生在30-50％ 患有急性非淋巴细胞白血病的患者可以构成分娩 潜在的治愈后缓解疗法。有很多 降低此发病率的潜在手段，其相对优点 在此赠款提案中讨论。马里兰大学癌症 中心（UMCC）有兴趣并准备参加随机分析 临床试验比较了输血的这些各种修饰 练习以合并血小板浓缩物的标准方法 随机捐助者。 UMCC是一个很好的环境 此类研究的出于以下原因：（1）有据可查的 30-40例急性非淋巴细胞性白血病的新患者的可用性 适用于学习/年度； （2）同一调查人员负责 白血病和输血服务保证 合规性和随机性； （3）UMCC已进行并发布 输血支持和血小板领域的多次研究 免疫学；这些包括许多随机研究，其中之一 这是一项使用白细胞耗尽血小板修饰的随机试验 同种免疫的速度； （4）UMCC在 合作癌症治疗组，并拥有多年的设施 有收集和转移研究数据的经验；另外 UMCC目前将所有血小板输血结果输入计算机化 用于临床和研究目的的数据库以及潜在的适应性 用于此RFA； （5）该提案的两个调查人员都主持 并分析了国家组临床治疗试验和P.I. 目前，主席是癌症和白血病组的白血病委员会。 与巴尔的摩RH打字实验室的分包合同作为 参考实验室执行淋巴细胞毒性抗体筛选是 提交为UMCC提案的补充。